We used exon array analysis confirmed by exon-specific PCR (ESPCR) to evaluate AML cells expressing various amounts of either DEK or WT1 and AML cells that show sensitivity or resistance to AraC, doxorubicin (DXR) or azacitidine (AZA). Here, DEK is linked to acute myeloid leukemia.